Core Viewpoint - SenesTech, Inc. has successfully closed the exercise of outstanding warrants, raising approximately $6.3 million, and issued new short-term warrants for additional capital [1][4]. Group 1: Financial Details - The company exercised warrants to purchase 1,458,872 shares at an exercise price of $4.15 per share [1]. - New unregistered short-term warrants were issued to purchase up to 2,188,308 shares at an exercise price of $5.25 per share, with a purchase price of $0.125 per warrant [3]. - The potential gross proceeds from the new short-term warrants, if fully exercised, could amount to approximately $11.5 million [4]. Group 2: Use of Proceeds - The net proceeds from the transaction are expected to be used for working capital and general corporate purposes [4]. Group 3: Company Overview - SenesTech is focused on humane management of animal pest populations through fertility control, with products like ContraPest® and Evolve™ [8]. - ContraPest® is the only U.S. EPA-registered contraceptive for male and female rats, while Evolve™ products are designated as minimum risk contraceptives for rodents [8].

Core Points - SenesTech, Inc. announced the closing of the exercise of outstanding warrants to purchase 1,458,872 shares of common stock at an exercise price of $2.90 per share, generating approximately $4.4 million in gross proceeds [1][4] - The company issued new unregistered short-term warrants for the same number of shares at an exercise price of $4.15 per share, with a purchase price of $0.125 per warrant, potentially raising an additional $6.0 million if fully exercised [3][4] - The net proceeds from the transaction are intended for working capital and general corporate purposes [4] Company Overview - SenesTech is focused on humane management of animal pest populations through fertility control, having developed products like ContraPest®, the only U.S. EPA-registered contraceptive for rats, and Evolve™ products for rodents [8]

Core Viewpoint - SenesTech, Inc. has entered into definitive agreements for the immediate exercise of outstanding warrants to purchase 1,458,872 shares of common stock at an exercise price of $2.90 per share, with the transaction expected to close around July 1, 2025 [1] Group 1: Warrant Exercise and Financial Details - The company will issue new unregistered short-term warrants to purchase an additional 1,458,872 shares at an exercise price of $4.15 per share, with a purchase price of $0.125 per warrant [3] - The gross proceeds from the exercise of existing warrants are expected to be approximately $4.4 million, while potential gross proceeds from the new short-term warrants could reach approximately $6.0 million if fully exercised [4] - The net proceeds from the transaction are intended for working capital and general corporate purposes [4] Group 2: Regulatory and Compliance Information - The resale of shares from the existing warrants has been registered under an effective registration statement on Form S-3 [5] - The new short-term warrants have not been registered under the Securities Act of 1933, and may not be offered or sold in the U.S. without an effective registration statement or applicable exemption [6] Group 3: Company Overview - SenesTech is focused on humane management of animal pest populations through fertility control, with products like ContraPest® and Evolve™ designed for effective pest management [8]